Vidac Pharma Holding (STU:T9G) Interest Expense : €-0.10 Mil (TTM As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vidac Pharma Holding's interest expense for the six months ended in Jun. 2024 was € -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vidac Pharma Holding's Operating Income for the six months ended in Jun. 2024 was € -0.50 Mil. Vidac Pharma Holding's Interest Expense for the six months ended in Jun. 2024 was € -0.01 Mil. Vidac Pharma Holding did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vidac Pharma Holding Interest Expense Historical Data

The historical data trend for Vidac Pharma Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding Interest Expense Chart

Vidac Pharma Holding Annual Data

Trend

Dec21

Dec22

Dec23

Interest Expense

-0.04

-0.08

Vidac Pharma Holding Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial			-0.01	-0.03	-	-0.09	-0.01

Vidac Pharma Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.10 Mil.

Vidac Pharma Holding (STU:T9G) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Vidac Pharma Holding's Interest Expense for the six months ended in Jun. 2024 was €-0.01 Mil. Its Operating Income for the six months ended in Jun. 2024 was €-0.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was €0.00 Mil.

Vidac Pharma Holding's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Vidac Pharma Holding did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Vidac Pharma Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Wenlock Road, 20-22, London, GBR, N1 7GU

Website

https://www.vidacpharma.com

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines